Investigational anticoagulants for hematological conditions: A new generation of therapies

Expert Opinion on Investigational Drugs

Volumn 22, Issue 10, 2013, Pages 1281-1294

  Denas, Gentian ^a   Pengo, Vittorio ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Antisense oligonucleotides (ASOs); Aptamers; Dual inhibitors FXa thrombin; Factor Xa inhibitors; New anticoagulants in the pipeline; PAR inhibitors; Thrombin inhibitors

Indexed keywords

ADOMIPARIN; ANTICOAGULANT AGENT; ANTISENSE OLIGONUCLEOTIDE; ATECEGATRAN METOXIL; ATOPAXAR; BETRIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; BMS 593214; DAREXABAN; ENOXAPARIN; EP 217609; ERIBAXABAN; FLOVAGATRAN; HEPARIN; LETAXABAN; LIGNIN; N [2 [4 (1 METHYL 4 PIPERIDINYL) 1 PIPERAZINYL] 2 OXO 1 PHENYLETHYL] 1H INDOLE 6 CARBOXAMIDE; OTAMIXABAN; PEGMUSIRUDIN; PEGNIVACOGIN; PRT 4445; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; RO 14; SEMULOPARIN; TANOGITRAN; TB 402; THROMBIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORAPAXAR; WARFARIN;

ANTICOAGULATION; ATHEROSCLEROSIS; BLOOD CLOTTING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FIBRIN FORMATION; FIBRINOLYSIS; HEART INFARCTION; HEMATOLOGIC DISEASE; HEMOSTASIS; HUMAN; INFLAMMATION; LONG TERM CARE; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SECONDARY PREVENTION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; TOTAL KNEE REPLACEMENT; URINARY EXCRETION; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; CLINICAL TRIALS AS TOPIC; DRUGS, INVESTIGATIONAL; HEMORRHAGE; HUMANS; THROMBOSIS; TREATMENT OUTCOME;

EID: 84884214540     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2013.821463     Document Type: Review

References (94)

1. De Caterina R, Husted S, Wallentin L, et al. New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. J Am Coll Cardiol 2012;59(16):1413-25.
2. Pengo V, Crippa L, Falanga A, et al. Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results. J Thromb Haemost 2012;10(10):1979-87
3. Denas G, Pengo V. Emerging anticoagulants. Expert Opin Emerg Drugs 2011;16(1):31-44
4. Garcia DA, Baglin TP, Weitz JI, Samama MM; American College of Chest P. Parenteral anticoagulants: antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e24S-43S
5. Hoffman M, Monroe DM III. A cell-based model of hemostasis. Thromb Haemost 2001;85(6):958-65
6. Shirk RA, Vlasuk GP. Inhibitors of factor VIIa/tissue factor. Arterioscler Thromb Vasc Biol 2007;27(9):1895-900
7. Howard EL, Becker KC, Rusconi CP, Becker RC. Factor IXa inhibitors as novel anticoagulants. Arterioscler Thromb Vasc Biol 2007;27(4):722-7
8. Lowenberg EC, Meijers JC, Monia BP, Levi M. Coagulation factor XI as a novel target for antithrombotic treatment. J Thromb Haemost 2010;8(11):2349-57
9. von Bruhl ML, Stark K, Steinhart A, et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med 2012;209(4):819-35.1
10. Weitz JI. Factor Xa and thrombin as targets for new oral anticoagulants. Thromb Res 2011;127(Suppl 2):S5-S12
11. Deinum J, Mattsson C, Inghardt T, Elg M. Biochemical and pharmacological effects of the direct thrombin inhibitor AR-H067637. Thromb Haemost 2009;101(6):1051-9
12. Johansson S, Cullberg M, Eriksson UG, et al. Single-dose pharmacokinetics, pharmacodynamics and safety of AZD0837, a novel oral direct thrombin inhibitor, in young healthy male subjects. Int J Clin Pharmacol Ther 2011;49(4):258-67
13. Olsson SB, Rasmussen LH, Tveit A, et al. Safety and tolerability of an immediate-release formulation of theoral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation. Thromb Haemost 2010;103(3):604-12
14. Lip GY, Rasmussen LH, Olsson SB, et al. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists. Eur Heart J 2009;30(23):2897-907
15. Lip GY, Rasmussen LH, Olsson SB, et al. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a Phase II study of AZD0837 in patients who are appropriate for but unable or unwilling to take vitamin K antagonist therapy. Thromb Res 2011;127(2):91-9
16. Paion AG. Paion reports positive preclinical results of its substance solulin in the indication haemophilia. [Press Release] 6 Dec. 2010. Available from: http://www.paion.de/images/stories/investoren/finanznachrichten/2010/en/ paionp101206en.pdf
17. Zhang P, Huang W, Wang L, et al. Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,Ndimethylcarbamimidoyl) benzamido)-5- methoxybenz amide, a highly potent, selective, and orally efficacious factor Xa inhibitor. Bioorg Med Chem Lett 2009;19(8):2179-85
18. Turpie AG, Bauer KA, Davidson BL, et al. A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT). Thromb Haemost 2009;101(1):68-76
19. Connolly SJ, Eikelboom J, Dorian P, et al. Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa). Eur Heart J 2013;34(20):1498-505
20. Iwatsuki Y, Sato T, Moritani Y, et al. Biochemical and pharmacological profile of darexaban, an oral direct factor Xa inhibitor. Eur J Pharmacol 2011;673(1-3):49-55
21. Groenendaal D, Strabach G, Garcia-Hernandez A, et al. The pharmacokinetics of darexaban are not affected to a clinically relevant degree by rifampicin, a strong inducer of P-glycoprotein and CYP3A4. Br J Clin Pharmacol 2013;75(2):440-9
22. Apostolakis S, Lip GY. Novel oral anticoagulants: focus on the direct factor Xa inhibitor darexaban. Expert Opin Investig Drugs 2012;21(7):1057-64
23. Turpie AGG, Lip GYH, Minematsu K, et al. Safety and tolerability of YM150 in subjects with non-valvular atrial fibrillation: a phase II study [abstract 1194]. Eur Heart J 2010;31(Abstr Suppl):173
24. Astellas Pharma, Inc. Astellas Pharma, Inc. Discontinues Development of Darexaban (YM150), an Oral Direct Factor Xa Inhibitor. [press release] 28 Sep. 2011. Available from: http://www.astellas.com/en/corporate/news/detail/astellas- pharma-incdiscontinu. html
25. Konishi N, Hiroe K, Kawamura M. Differential effects of TAK-442, a novel orally active direct factor Xa inhibitor, and ximelagatran, a thrombin inhibitor, on factor V-mediated feedback on coagulation cascade and bleeding. Thromb Haemost 2010;104(3):504-13
26. Weitz JI, Cao C, Eriksson BI, et al. A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery. Thromb Haemost 2010;104(6):1150-7
27. Goldstein S, Bates E, Bhatt D, et al. Safety evaluation of the factor Xa inhibitor TAK-442 in subjects with acute coronary syndromes: phase 2 AXIOM-ACS trial results. Eur Heart J 2011;32(Suppl): abstract #2430
28. Agnelli G, Haas S, Ginsberg JS, et al. A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement. J Thromb Haemost 2007;5(4):746-53
29. Hinder M, Frick A, Jordaan P, et al. Direct and rapid inhibition of factor Xa by otamixaban: a pharmacokinetic and pharmacodynamic investigation in patients with coronary artery disease. Clin Pharmacol Ther 2006;80(6):691-702
30. Cohen M, Bhatt DL, Alexander JH, et al. Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial. Circulation 2007;115(20):2642-51
31. Sabatine MS, Antman EM, Widimsky P, et al. Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial. Lancet 2009;374(9692):787-95
32. Steg PG, Mehta SR, Pollack CV Jr., et al. Design and rationale of the treatment of acute coronary syndromes with otamixaban trial: a double-blind triple-dummy 2-stage randomized trial comparing otamixaban to unfractionated heparin and eptifibatide in non-ST-segment elevation acute coronary syndromes with a planned early invasive strategy. Am Heart J 2012;164(6):817-24; e13
33. Sanofi. Sanofi provides update on phase III studies of two investigational compounds. [press release] 3 Jun. 2013. Available from: http://www.sanofi.co.uk/l/gb/en/layout.jsp?cnt=BDFF7A0E-6FC6-4DB4-B124- 09A4D9D39400
34. Abdel Aziz MH, Mosier PD, Desai UR. Identification of the site of binding of sulfated, low molecular weight lignins on thrombin. Biochem Biophys Res Commun 2011;413(2):348-52
35. Henry BL, Thakkar JN, Liang A, Desai UR. Sulfated, low molecular weight lignins inhibit a select group of heparin-binding serine proteases. Biochem Biophys Res Commun 2012;417(1):382-6
36. de Kort M, Buijsman RC, van Boeckel CA. Synthetic heparin derivatives as new anticoagulant drugs. Drug Discov Today 2005;10(11):769-79
37. Olson ST, Swanson R, Petitou M. Specificity and selectivity profile of EP217609: a new neutralizable dual-action anticoagulant that targets thrombin and factor Xa. Blood 2012;119(10):2187-95
38. Vogel GM, Meuleman DG, Van Dinther TG, et al. Antithrombotic properties of a direct thrombin inhibitor with a prolonged half-life and AT-mediated factor Xa inhibitory activity. J Thromb Haemost 2003;1(9):1945-54
39. Petitou M, Nancy-Portebois V, Dubreucq G, et al. From heparin to EP217609: the long way to a new pentasaccharide-based neutralisable anticoagulant with an unprecedented pharmacological profile. Thromb Haemost 2009;102(5):804-10
40. Endotis Pharma. Endotis Pharma presents Phase I clinical trial results for a first-in-class synthetic parenteral neutralizable anticoagulant EP217609 at the 21st International Congress on Thrombosis. [press release] 8 Jul. 2010. Available from: http://www.endotis.com/news/document-1279012503596.pdf
41. Graefe-Mody EU, Schuhly U, Rathgen K, et al. Pharmacokinetics and pharmacodynamics of BIBT 986, a novel small molecule dual inhibitor of thrombin and factor Xa. J Thromb Haemost 2006;4(7):1502-9
42. Leitner JM, Jilma B, Mayr FB, et al. Pharmacokinetics and pharmacodynamics of the dual FII/FX inhibitor BIBT 986 in endotoxin-induced coagulation. Clin Pharmacol Ther 2007;81(6):858-66
43. Kasthuri RS, Taubman MB, Mackman N. Role of tissue factor in cancer. J Clin Oncol 2009;27(29):4834-8
44. Carr C, Bild GS, Chang AC, et al. Recombinant E. coli-derived tissue factor pathway inhibitor reduces coagulopathic and lethal effects in the baboon gram-negative model of septic shock. Circ Shock 1994;44(3):126-37
45. Wunderink RG, Laterre PF, Francois B, et al. Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2011;183(11):1561-8
46. Lee A, Agnelli G, Buller H, et al. Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Circulation 2001;104(1):74-8
47. Giugliano RP, Wiviott SD, Stone PH, et al. Recombinant nematode anticoagulant protein c2 in patients with non-ST-segment elevation acute coronary syndrome: the ANTHEM-TIMI-32 trial. J Am Coll Cardiol 2007;49(25):2398-407
48. Wong PC, Luettgen JM, Rendina AR, et al. BMS-593214, an active site-directed factor VIIa inhibitor: enzyme kinetics, antithrombotic and antihaemostatic studies. Thromb Haemost 2010;104(2):261-9
49. Muller F, Gailani D, Renne T. Factor XI and XII as antithrombotic targets. Curr Opin Hematol 2011;18(5):349-55
50. Wong PC, Crain EJ, Watson CA, Schumacher WA. A small-molecule factor XIa inhibitor produces antithrombotic efficacy with minimal bleeding time prolongation in rabbits. J Thromb Thrombolysis 2011;32(2):129-37
51. Schumacher WA, Seiler SE, Steinbacher TE, et al. Antithrombotic and hemostatic effects of a small molecule factor XIa inhibitor in rats. Eur J Pharmacol 2007;570(1-3):167-74
52. Wong PC, Jiang X. Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin. Thromb Haemost 2010;104(2):302-10
53. Hagedorn I, Schmidbauer S, Pleines I, et al. Factor XIIa inhibitor recombinant human albumin Infestin-4 abolishes occlusive arterial thrombus formation without affecting bleeding. Circulation 2010;121(13):1510-17
54. Decrem Y, Rath G, Blasioli V, et al. Ir-CPI, a coagulation contact phase inhibitor from the tick Ixodes ricinus, inhibits thrombus formation without impairing hemostasis. J Exp Med 2009;206(11):2381-95
55. Eikelboom JW, Zelenkofske SL, Rusconi CP. Coagulation factor IXa as a target for treatment and prophylaxis of venous thromboembolism. Arterioscler Thromb Vasc Biol 2010;30(3):382-7
56. Eriksson BI, Dahl OE, Lassen MR, et al. Partial factor IXa inhibition with TTP889 for prevention of venous thromboembolism: an exploratory study. J Thromb Haemost 2008;6(3):457-63
57. Zhang H, Lowenberg EC, Crosby JR, et al. Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk. Blood 2010;116(22):4684-92
58. Dias N, Stein CA. Antisense oligonucleotides: basic concepts and mechanisms. Mol Cancer Ther 2002;1(5):347-55
59. Liu Q, Bethune C, Dessouki E, et al. Isis-fxirx, a novel and specific antisense inhibitor of factor XI, significantly reduces fXI antigen and activity and increases aPTT without causing bleeding in healthy volunteers. Blood 2011;118:209
60. Revenko AS, Gao D, Crosby JR, et al. Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding. Blood 2011;118(19):5302-11
61. Renne T, Schmaier AH, Nickel KF, et al. In vivo roles of factor XII. Blood 2012;120(22):4296-303
62. Keefe AD, Pai S, Ellington A. Aptamers as therapeutics. Nat Rev Drug Discov 2010;9(7):537-50
63. Rusconi CP, Roberts JD, Pitoc GA, et al. Antidote-mediated control of an anticoagulant aptamer in vivo. Nat Biotechnol 2004;22(11):1423-8
64. Lancellotti S, De Cristofaro R. Nucleotide-derived thrombin inhibitors: a new tool for an old issue. Cardiovasc Hematol Agents Med Chem 2009;7(1):19-28
65. Muller J, Freitag D, Mayer G, Potzsch B. Anticoagulant characteristics of HD1-22, a bivalent aptamer that specifically inhibits thrombin and prothrombinase. J Thromb Haemost 2008;6(12):2105-12
66. Kretz CA, Stafford AR, Fredenburgh JC, Weitz JI. HD1, a thrombin-directed aptamer, binds exosite 1 on prothrombin with high affinity and inhibits its activation by prothrombinase. J Biol Chem 2006;281(49):37477-85
67. Dyke CK, Steinhubl SR, Kleiman NS, et al. First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity. Circulation 2006;114(23):2490-7
68. Povsic TJ, Wargin WA, Alexander JH, et al. Pegnivacogin results in near complete FIX inhibition in acute coronary syndrome patients: RADAR pharmacokinetic and pharmacodynamic substudy. Eur Heart J 2011;32(19):2412-19
69. Chan MY, Cohen MG, Dyke CK, et al. Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease. Circulation 2008;117(22):2865-74
70. Cohen MG, Purdy DA, Rossi JS, et al. First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary intervention. Circulation 2010;122(6):614-22
71. Povsic TJ, Vavalle JP, Aberle LH, et al. A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial. Eur Heart J 2012. [Epub ahead of print]
72. Ahrens I, Putz V, Zelenkofske SL, et al. Reg1, a Novel RNA-Aptamer Direct Factor IXa-inhibitor (pegnivacogin) Reduces Platelet Activation in Healthy Volunteers and Residual Platelet Aggregation in Patients with ACS. A Radar Substudy. Circulation 2011;124:A9771
73. Vavalle JP, Rusconi CP, Zelenkofske S, et al. A phase 1 ascending dose study of a subcutaneously administered factor IXa inhibitor and its active control agent. J Thromb Haemost 2012;10(7):1303-11
74. Regado Biosciences, Inc. Regado Biosciences, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference in Boston, MA. [press release] 8 Aug. 2012. Available from: http://www.regadobio.com/index.php/2012/08/ regadobiosciences-inc-to-present-at-thecanaccord-genuity-32nd-annual- growthconference-in-boston-ma-2/
75. Jacquemin M, Stassen JM, Saint-Remy JM, et al. A human monoclonal antibody inhibiting partially factor VIII activity reduces thrombus growth in baboons. J Thromb Haemost 2009;7(3):429-37
76. Verhamme P, Pakola S, Jensen TJ, et al. Tolerability and pharmacokinetics of TB-402 in healthy male volunteers. Clin Ther 2010;32(6):1205-20
77. Tangelder M, Long C, Emmerechts J, et al. Antidote strategies to reverse anticoagulation with TB-402, a long-acting partial inhibitor of factor VIII. J Thromb Haemost 2012;10(7):1371-8
78. Verhamme P, Tangelder M, Verhaeghe R, et al. Single intravenous administration of TB-402 for the prophylaxis of venous thromboembolism after total knee replacement: a dose-escalating, randomized, controlled trial. J Thromb Haemost 2011;9(4):664-71
79. Ranieri VM, Thompson BT, Barie PS, et al. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012;366(22):2055-64
80. Williams PD, Zlokovic BV, Griffin JH, et al. Preclinical safety and pharmacokinetic profile of 3K3A-APC, a novel, modified activated protein C for ischemic stroke. Curr Pharm Des 2012;18(27):4215-22
81. ZZ Biotech. ZZ Biotech Initiates Phase 1 Study with 3K3A-APC for the Treatment of Acute Ischemic Stroke. [press release] 8 Aug. 2012. Available from: http://zzbiotech.com/zz/8Aug2012a.html
82. Hamilton JR. Protease-activated receptors as targets for antiplatelet therapy. Blood Rev 2009;23(2):61-5
83. Ruf W, Dorfleutner A, Riewald M. Specificity of coagulation factor signaling. J Thromb Haemost 2003;1(7):1495-503
84. Tricoci P, Huang Z, Held C, et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 2012;366(1):20-33
85. Scirica BM, Bonaca MP, Braunwald E, et al. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2 degrees P-TIMI 50 trial. Lancet 2012;380(9850):1317-24
86. Morrow DA, Braunwald E, Bonaca MP, et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012;366(15):1404-13
87. Bonaca MP, Scirica BM, Creager MA, et al. Vorapaxar in Patients With Peripheral Artery Disease: results From TRA2oP-TIMI 50. Circulation 2013;127(14):1522-9
88. Morrow DA, Alberts MJ, Mohr JP, et al. Efficacy and safety of vorapaxar in patients with prior ischemic stroke. Stroke 2013;44(3):691-8
89. Leonardi S, Tricoci P, White HD, et al. Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRAoCER) trial. Eur Heart J 2013;34(23):1723-31
90. Merck. Merck Provides Update on Cardiovascular Development Programs. [press release] 26 Aug. 2012. Available from: http://www.mercknewsroom.com/ press-release/research-and-development-news/merckprovides-update- cardiovasculardevelopment-program
91. O'Donoghue ML, Bhatt DL, Wiviott SD, et al. Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin-Acute Coronary Syndromes Trial. Circulation 2011;123(17):1843-53
92. O'Donoghue ML, Bhatt DL, Flather MD, et al. Atopaxar and its effects on markers of platelet activation and inflammation: results from the LANCELOT CAD program. J Thromb Thrombolysis 2012;34(1):36-43
93. Heidbuchel H, Verhamme P, Alings M, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013;15(5):625-51
94. Ansell J. New oral anticoagulants should not be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation. Circulation 2012;125(1):165-70; discussion 70